AtriCure Launches cryoXT for Post-Op Pain Management After Amputation

AtriCure has launched its cryoXT device, a cryoablation technology to manage post-operative pain after amputation procedures.

The company’s cryoICE platform uses a novel freezing method to block nerve pain signals. By introducing cryoXT, physicians can access a next-gen tool that provides a long-lasting approach to post-amputation pain management.

Recently cleared by the U.S. Food and Drug Administration (FDA) under a 510(k), cryoXT was designed to temporarily block pain after amputation by ablating peripheral nerves. The device builds on AtriCure’s cryoSPHERE devices, which have been used in over 100,000 procedures since FDA clearance in November 2018.

The new device touts a newly designed tip with multi-surface freezing tech to precisely target large diameter exposed peripheral nerves.

“The launch of the cryoXT device reflects our commitment to bringing meaningful, differentiated solutions to patients and providers in a significant and underserved segment of the surgical market,” said Michael Carrel, President and CEO of AtriCure. “We’re addressing a clear gap in post-amputation care by helping more patients successfully manage pain. It’s a powerful combination of doing good and expanding AtriCure’s growth pathways.”

“As an orthopedic surgeon, managing long-term pain after limb loss is a critical part of patient care,” added Dr. Bryan Houseman, DO, Orthopedic Surgeon at The Elliot Hospital in Manchester, NH. “The cryoXT device allows us to address pain at the time of surgery effectively, improving both recovery and quality of life, and represents a significant advancement in reducing post-surgical pain for our patients.”

Earlier this year, the company announced the first use of its newest AtriClip device for minimally invasive concomitant procedures, the AtriClip PRO-Mini LAA (left atrial appendage) exclusion system.